NCT06427226View on ClinicalTrials.gov

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

August 1, 2025

Conditions
Doxorubicin Induced CardiomyopathyBreast Cancer
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10 mg tab once daily given during the duration of AC cycles.

Trial Locations (1)

21526

Medical Research Institute, Alexandria

All Listed Sponsors
lead

Tanta University

OTHER

NCT06427226 - Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity | Biotech Hunter | Biotech Hunter